FDA approves launch of AbbVie IL-23-specific inhibitor Skyrizi (risankizumab)

today, AbbVie(http://announced that itFDA(http://approved its development of the IL-23-specific inhibitor Skyrizi (risankizumab) for the treatment of patients with severe psoriasisIn clinicaltrial(http://, Skyrizi was able to remove skin symptoms highly, with 90% of the skin symptoms disappeared (PASI 90) one year after treatment in the majority of patients treated (PASI 90), and more than half of the patients disappeared completely (PASI 100)Skyrizi is a potential heavyweight anti-inflammatorydrug(http://developed by Abbot and Boehringer IngelheimIt is a human-derived monoclonal antibody targeting IL-23, which can selectively block the IL-23 signaling pathway by combining with the p19 sub-base of IL-23Skyrizi has just been named one of the most high
-profile http:// by Coreveh, which is likely to become a blockbuster by 2023 　　Skyrizi's approval is based on AbbVie's global psoriasis clinical program, which includes four Phase 3 clinical trials 　　In Phase 3 clinical trials called ultIMMa-1 and ultIMMa-2, after 16 weeks of treatment with Skyrizi, 75% of patients reached PASI 90, 36% and 51% of patients reached PASI 100 　　After 52 weeks of treatment with Skyrizi, 82% and 81% of patients reached PASI 90, 56% and 60% of patients reached PASI 100 　　A combination of data from the ultIMMa-1 and ultIMMa-2 trials combined with data
from the ultIMMa-1 and ultIMMa-2 trials (http:// showed that the majority of patients who reached PASI 90 and PASI 100 at 16 weeks of treatment were able to maintain symptom asymptomatic remission (88% and 80%, respectively)